ストックスクリーナーアプリを入手
8.50
0.00%
0.00
アフターアワーズ：
8.50
前日終値:
$8.50
開ける：
$8.5
24時間の取引高:
835.54K
Relative Volume:
0.23
時価総額：
$797.33M
収益：
$324.00K
当期純損益:
$-82.10M
株価収益率:
-9.1398
EPS:
-0.93
ネットキャッシュフロー:
$-69.18M
1週間 パフォーマンス:
+0.00%
1か月 パフォーマンス:
+79.32%
6か月 パフォーマンス:
+852.49%
1年 パフォーマンス:
+701.89%
1日の値動き範囲:
$8.50
$8.51
1週間の範囲:
$8.49
$8.53
52週間の値動き範囲:
$0.75
$8.53
Chimerix Inc Stock (CMRX) Company Profile
名前
Chimerix Inc
セクター
電話
919.806.1074
住所
2505 MERIDIAN PARKWAY, SUITE 100, DURHAM, NC
CMRX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CMRX
Chimerix Inc
|
8.50 | 797.33M | 324.00K | -82.10M | -69.18M | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Chimerix Inc Stock (CMRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-05-23 | 開始されました | Robert W. Baird | Outperform |
| 2022-09-07 | 開始されました | CapitalOne | Overweight |
| 2021-04-29 | 開始されました | Maxim Group | Buy |
| 2021-04-23 | 再開されました | Cowen | Outperform |
| 2021-03-31 | 開始されました | Jefferies | Buy |
| 2021-03-31 | 開始されました | Wedbush | Outperform |
| 2018-02-14 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2018-02-02 | 開始されました | H.C. Wainwright | Buy |
| 2016-08-09 | 繰り返されました | FBR Capital | Mkt Perform |
| 2016-02-23 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2016-02-23 | 繰り返されました | FBR Capital | Mkt Perform |
| 2016-02-23 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2016-02-22 | ダウングレード | Citigroup | Buy → Neutral |
| 2015-12-29 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2015-12-28 | ダウングレード | FBR Capital | Outperform → Mkt Perform |
| 2015-12-28 | 繰り返されました | Piper Jaffray | Overweight |
| 2015-12-17 | 開始されました | UBS | Buy |
| 2015-10-05 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2015-09-03 | 開始されました | Citigroup | Buy |
| 2015-08-18 | 開始されました | FBR Capital | Outperform |
| 2015-08-06 | 繰り返されました | Brean Capital | Buy |
| 2015-05-11 | 繰り返されました | Brean Capital | Buy |
| 2015-03-04 | 開始されました | Barclays | Overweight |
| 2015-02-12 | 繰り返されました | Stifel | Buy |
| 2014-12-31 | 繰り返されました | Brean Capital | Buy |
| 2014-07-08 | 再開されました | Brean Capital | Buy |
すべてを表示
Chimerix Inc (CMRX) 最新ニュース
Chimerix Inc. (NASDAQ:CMRX) Amazing Performance So Far In 2025 - Yahoo Finance
Chimerix stock soars to 52-week high, hits $8.53 By Investing.com - Investing.com South Africa
Chimerix stock soars to 52-week high, hits $8.53 - Investing.com
11 Best Performing Stocks So Far In 2025 - Insider Monkey
Chimerix earnings missed, revenue fell short of estimates By Investing.com - Investing.com Canada
Chimerix Inc Reports Q4 2024 EPS of -$0.25, Beating Estimates; R - GuruFocus.com
The buildup to Chimerix's $935M exit to Jazz, with more than half a dozen parties intrigued - Endpoints News
Chimerix: Q4 Earnings Snapshot - mySA
Chimerix Inc. (CMRX) reports earnings - Quartz
CHIMERIX INC SEC 10-K Report - TradingView
Chimerix Reports Fourth Quarter and Year End 2024 Financial Results - The Manila Times
Chimerix: Q4 Earnings Snapshot -March 21, 2025 at 06:07 am EDT - Marketscreener.com
Chimerix Reports Earnings as $935M Jazz Buyout and FDA Drug Review Advance - StockTitan
Investment Analysts’ Recent Ratings Updates for Chimerix (CMRX) - Defense World
Chimerix stock soars to 52-week high, hits $8.47 By Investing.com - Investing.com Australia
Chimerix stock soars to 52-week high, hits $8.47 - Investing.com India
Ireland: Jazz adds to oncology pipeline with Chimerix - Investors in Healthcare
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RDFN, BLBX, CMRX, WBA on Behalf of Shareholders - GlobeNewswire Inc.
Kuehn Law Encourages BRDG, CMRX, WBA and SYTA Investors to Contact Law Firm - The Malaysian Reserve
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: 2seventy bio, Inc. (NasdaqTSVT), Bridge Investment Group Holdings Inc. (NYSEBRDG), Chimerix, Inc. (NasdaqCMRX), 180 Degree Capital Corp. (Nasda - Morningstar
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CMRX, WBA, BLUE on Behalf of Shareholders - Finansavisen
CHIMERIX INVESTOR ALERT by the Former Attorney General of Louisi - WICZ
Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Chimerix, Inc. - Financial Content
CHIMERIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Chimerix, Inc.CMRX - Business Wire
Why Chimerix, Inc. (CMRX) Soared Last Week - Insider Monkey
10 Micro-, Small-Cap Firms Were Last Week’s Top Performers - Insider Monkey
Chimerix Expands Team with Strategic New Hire, Offers 70K Share Options Package - StockTitan
Chimerix, Inc. to Host Earnings Call - ACCESS Newswire
CMRX Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Chimerix, Inc. is Fair - Bluefield Daily Telegraph
CMRX Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Chimerix, Inc. is Fair to Shareholders - GlobeNewswire
HC Wainwright Reiterates “Neutral” Rating for Chimerix (NASDAQ:CMRX) - Defense World
Top Medical Stocks To Add to Your Watchlist – March 5th - Defense World
Jefferies Financial Group Reaffirms Hold Rating for Chimerix (NASDAQ:CMRX) - Defense World
The Zacks Analyst Blog Jazz Pharmaceuticals, Chimerix, Moderna, GSK and Regeneron Pharmaceuticals - Nasdaq
Best Pharmaceutical Stocks To Watch Today – March 5th - Defense World
Wedbush Reaffirms “Neutral” Rating for Chimerix (NASDAQ:CMRX) - Defense World
Biotech Stocks Roundup: CMRX Up on JAZZ Bid, MRNA Up on Updates & More - TradingView
Truist Raises PT on Jazz Pharmaceuticals to $230 From $220 on Heels of Announced Purchase of Chimerix, Keeps Buy Rating - Marketscreener.com
Jazz Offers to Buy Chimerix for $935M to Boost Oncology Portfolio - MSN
Jazz Offers To Buy Chimerix For $935M To Boost Oncology Portfolio - Barchart
Chimerix downgraded to Neutral from Buy at H.C. Wainwright - Yahoo Finance
This MongoDB Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday - Benzinga India
Jazz Pharmaceuticals to acquire Chimerix for $935m - World Pharmaceutical Frontiers
Jazz Pharma to acquire Chimerix for ~$935M in cash - MSN
Jazz Pharmaceuticals bids for Chimerix in $935m deal - MSN
CrowdStrike reports Q4 beat, Jazz to acquire Chimerix: Morning Buzz - MSN
Jazz to Acquire Chimerix for $935M, Expanding Rare Oncology Portfolio - Genetic Engineering & Biotechnology News
Jazz Pharmaceuticals to acquire Chimerix for $935 million By Investing.com - Investing.com Canada
Chimerix brings a rare cancer drug to the $935M Jazz party - BioWorld Online
Chimerix Stock Hold Rating: Limited Upside Due to Acquisition Offer Price Alignment - TipRanks
Chimerix Inc (CMRX) 財務データ
収益
当期純利益
現金流量
EPS
0.39%
0.34%
大文字化:
|
ボリューム (24 時間):